Skip to main content
RUBICON · Health Care · 2026-08-07

Rubicon Research Ltd

MARKET: BULL TOPPING · 2026-08-07
₹1,553.2
+1.29% today
₹25,642 Cr · Large cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.

Visit company website →
P/E (TTM)
77.3
Forward 48.8
Earnings Growth (YoY)
+79.3%
Revenue +51.7%
vs 52W High
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 41
1w13w26w
Week 41 — mature, watch for distribution
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
0.16x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
MA20 trending up · +5.1% vs MA50 +18.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Industry has 53 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2025-10-16 → 2026-08-07
S? 42w
2025-10-162026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w current
Total tracked: 42 weeks across 1 stage run.
1M
+10.4%
3M
+62.5%
6M
+125.5%
YTD
+127.7%
1Y
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-08-07S
Wk 41 · Vol x
2026-08-06S
Wk 41 · Vol x
2026-08-05S
Wk 41 · Vol x
2026-08-04S
Wk 40 · Vol x
2026-08-03S
Wk 40 · Vol x
2026-07-31S
Wk 40 · Vol x
2026-07-30S
Wk 40 · Vol x
2026-07-29S
Wk 40 · Vol x
2026-07-28S
Wk 39 · Vol x
2026-07-27S
Wk 39 · Vol x
2026-07-24S
Wk 39 · Vol x
2026-07-23S
Wk 39 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹1,391.7
200 DMA
52W High
52W Low
5D Low
₹1,500.8
Resistance levels (recent highs)
20d High
₹1,574.6
60d High
₹1,574.6
120d High
₹1,574.6
250d High
Next resistance
+1.4%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.